Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...
The iGaN Laboratory led by Haiding Sun at the University of Science and Technology of China (USTC) has proposed a novel ...
The firm, which notes that Vera is conducting the Phase 3 ORIGIN 3 study of 150 mg atacicept in patients with IgAN while utilizing at-home administration with once-weekly dosing, reiterates a Buy ...
Having been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Despite potential volatility ahead of the readouts, “We continue to recommend the stock as the profile is greatly derisked & will benefit from first-ish mover advantage in IgAN, a field ...
The company has received FDA Breakthrough Therapy Designation for atacicept in IgAN, which could signify a substantial improvement over existing therapies. Vera reported a net loss of $152.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback